We report here the design, synthesis, and in vitro characterization of new opioid peptides featuring a 4-anilidopiperidine moiety. Despite the fact that the chemical structures of fentanyl surrogates have been found suboptimal per se for the opioid activity, the corresponding conjugates with opioid peptides displayed potent opioid activity. These studies shed an instructive light on the strategies and potential therapeutic values of anchoring the 4-anilidopiperidine scaffold to different classes of opioid peptides.
KeywordsOpioid peptide; Dynorphine analog; Bivalent ligand; Fentanyl; AnalgesicThe increasing need for effective pain management prompts the invention of new strategies and pharmacological tools. Among the three opioid receptor types (μ, δ, and κ, the μ-opioid receptor is considered to be essential for efficient pain suppression. However, μ-opioids do not provide adequate treatment of chronic pain since their long-term use results in multiple side effects (e.g., 1 ). Close examination of the opioid system conferred that a μ-δ opioid receptor heterodimer represents the fundamental signaling unit responsible for opioid tolerance and dependence. 2,3 During the last two decades, our laboratory has carried out extensive research on the synthesis of novel opioid analogs. Within the frame of our works on bivalent opioid ligands there seemed a gap between small-molecule and peptide-based opioids. We have sought to bridge this gap by incorporating the 4-ANDP 4 scaffolds into opioid peptides, and also to optimize their physicochemical properties. [5][6][7] Previously, research efforts to produce bivalent opioid peptides resulted in analogs with exceptional properties. One representative example is biphalin. 8 Despite numerous advantages such as low toxicity, high activity and specificity, opioid peptides are still not being used as painrelieving agents in general anesthetic practice because of main drawbacks such as poor bioavailability after systemic (subcutaneous or oral) administration, limited ability to cross the blood-brain barrier, and rapid degradation in vivo by peptidases. Although the fact that fentanyl 9-12 is a bioavailable drug does not directly suggest that its addition to a peptide structure will yield a bioavailable hybrid, we hypothesized that its incorporation into opioid peptides may positively impact overall bioavailability of the latter.
NIH Public Access
NIH-PA Author ManuscriptNIH-PA Author Manuscript
NIH-PA Author ManuscriptA careful analysis of the literature revealed that in the series of fentanyl analogs there was no general consensus regarding the effect of substitution in the propionyl part of the molecule. We thus set out to prepare the desired compound by using Fmoc-and Phtprotected amino acid chlorides (Scheme 1). This allowed us to synthesize 3-aminofentanyl and analogs 1-6. The synthesis, NMR characterization and binding affinity at the μ and δ opioid receptors of compounds 7-12 have been reported previously by us, 5 but no results of GPI and MVD assays were provided...